The revenue realized in the first half of 2019 has exceeded the whole year of last year. It is expected that by the end of 2019, the annual revenue scale will be expected to increase by 2~3 times.

It is reported that DNA synthesis technology company “Di Win Bio” has recently completed a new round of financing of tens of millions of yuan, led by Volcanic Stone Capital.

BCC Research Forecast, Global Synthesis The market size of biology will grow from $4.4 billion in 2017 to $13.9 billion in 2022, with a compound annual growth rate of 26.0%. Due to the high technical barriers, there are not many players involved in the field of DNA synthesis in China, including Diwin Bio, 泓 Xun Technology, Platinum Bio and other companies.

Shanghai Diwin Biotechnology Co., Ltd. (hereinafter referred to as Diwin Bio) was established in 2018. In January, it was an innovative high-tech company dedicated to the development and application of synthetic biology. At this stage, the company has successfully developed Micropore high-throughput DNA synthesis platform with independent intellectual property rights and the original QuarXeq double-stranded RNA probe capture technology. Based on the above platform technology, it has launched a variety of products, including: complete solution of liquid biopsy Protocols, liquid-based probe capture and amplicon capture of various NGS library capture kits, probes and oligonucleotide pool design synthesis services, as well as supporting automated workstation solutions.

In terms of the company’s operating conditions, Diwin Bio CEO Chen Yuqun said that Diwin Bio has now covered a number of hospitals and third-party medical testing institutes, biomedical research and development companies, universities and research institutes, IVD companies and other units. The revenue realized in the first half of 2019 has exceeded the whole year of last year. It is expected that by the end of 2019, the annual revenue scale will be expected to increase by 2~3 times.

Team, Diwin has created a multidisciplinary team of young people including 9 doctors, 11 masters and 9 undergraduates.

The company’s chairman and chief scientist, Shi Yong, is a special and long-term professor at Shanghai Jiaotong University (DistinGuished/Tenure Professor), Minister of Education Jiang Scholar Distinguished Professor, National Outstanding Youth Science Fund winner; CEO Chen Yuqun, graduated from Fudan University, Department of Biochemistry, formerly a biochemistry research assistant at the University of Hong Kong, with 15 years of molecular biology technical services CTO Zhang Mancang, graduated from East China Normal University with a master’s degree in genomics, has more than 10 years of experience in high-throughput sequencing (NGS), and has served as a senior technical officer in ABI, Agilent, Twist and other multinational companies.

For investment logic, Liu Kai, vice president of volcanic stone capital, said that on the one hand, the team of Diwin Bio is led by first-class scientists, and many founders with experience in industrialization of various disciplines join; on the other hand, the company is At the beginning of the establishment, there will be a clear application direction, and the strategic development plan at each stage is clear.